On October 21, 2021 Tallac Therapeutic reported that it will present new data from ALTA-002, a SIRPα-directed TLR9 agonist antibody conjugate from our Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to promote anti-tumor immunity at the upcoming SITC (Free SITC Whitepaper) annual meeting taking place Nov. 10–14, 2021 in Washington, DC (Press release, Tallac Therapeutics, OCT 21, 2021, View Source [SID1234591696])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title:
ALTA-002, a SIRPα-directed TLR9 agonist antibody conjugate activates myeloid cells and promotes anti-tumor immunity (Abstract 780)

Presentation Time:
November 12 – 14, 2021, 7:00am – 5:00pm ET

Location:
Poster Hall